Evidence map›Paper›PMID 35235018›Full record

ArticleWorld journal of urology2022

Trends in the cause of death among patients with bladder cancer in the US SEER population, 1992-2018.

Xiangpeng Zhan, Luyao Chen, Ming Jiang, Bin Fu

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Long-term Trends in Bladder Cancer Incidence Using a Harmonized Staging Variable: A SEER-Based Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Xiangpeng Zhan *Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Luyao Chen *Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Ming JiangDepartment of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China.
Bin FuDepartment of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Province, China. urofbin@163.com.ORCID http://orcid.org/0000-0001-6686-7561
Nanchang University · CN

Funding

the National Natural Science Foundation of P.R. China 81960512
6 · The paper itself

Abstract

backgroundBladder cancer (BC) survival has shown no significant improvement. This study investigated the trends in the common causes of death among patients with BC to improve the management and survival of BC.

methodThe Surveillance, Epidemiology, and End Results (SEER) (1992-2018) database was utilized to get the data of BC patients. We presented the proportion of six common causes of death in BC patients. We calculated the annual incidence of death due to the six most common causes and analyzed temporal trends in mortality rates using joinpoint regression. The competitive risk model was utilized to analyze the risk factors for death of BC and other causes.

results198037 BC patients were enrolled. BC was the most common cause of death (30.62%), followed by other cancers (22.22%), circulatory diseases (20.28%), non-disease causes (11.58%), other non-cancer diseases (8.29%), and respiratory diseases (7.01%). However, the proportion of cases dying from BC gradually decreased from 44.87% in 1992-1996 to 26.74% in 2012-2018. The proportion of deaths due to BC decreased gradually with survival time from diagnosis. Age-standardized temporal trends present an initial increase in BC-specific and other-cause mortality rates. Advanced stage and older age were the most influential risk factors for BC-specific and other-cause death, respectively.

conclusionAlthough BC was still the leading cause of death, other causes, especially other cancers and circulatory diseases, gradually became more critical. The management of other comorbid conditions will be a crucial part of the treatment for BC patients, especially for those with prolonged survival and NMIBC tumors.

Indexed as

Urinary Bladder NeoplasmsCause of DeathHumansIncidenceRisk FactorsSEER ProgramBladder cancerCause of deathSEERTemporal trends

Identifiers

PMID35235018
OpenAlexW4214830681

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.